stockrow
Saturday 7 November 2026
Export TVGN’s income statement to Excel — free account
Tevogen Inc.
TVGN Healthcare Biotechnology
- EPS
- +11.1%
- Free cash flow
- +5.78%
- Total debt
- +45.5%
Quarter to June 2026, against a year earlier
5.35
0.21
−3.78%
Follow TVGN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 502 | 502 | — | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | 0 | 4 | (60) | (14) | (26) | (22) | +450.1% | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | — | — | 0 | 4 | (60) | (14) | (26) | (22) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | (0.11) | 16.41 | (122.17) | (3.50) | (8.08) | (6.20) | +192.8% | ||||||
| Cash flow | — | — | — | — | — | (2.98) | (0.80) | (16.51) | (4.09) | (3.71) | (3.02) | +5.7% | ||||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | (0.27) | 0.00 | (0.02) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | (2.98) | (0.80) | (16.78) | (4.09) | (3.73) | (3.02) | +5.8% | ||||||
| Book value | — | — | — | — | — | (59.36) | (55.02) | (190.77) | (2.28) | (2.48) | (2.32) | (54.8%) | ||||||
| Shares, m | — | — | — | — | — | 0 | 0 | 0 | 3 | 3 | 4 | +92.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | 0 | (8) | (12) | (12) | (12) | +103.9% | |||||
| Capex | — | — | — | — | — | — | — | 0 | — | 0 | 0 | (30.4%) | ||||||
| Free cash flow | — | — | — | — | — | (1) | 0 | (8) | (12) | (12) | (12) | +104.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 1 | 0 | (84) | (7) | (6) | (4) | n/m | |||||
| Net debt | — | — | — | — | — | 0 | 0 | 13 | 0 | 4 | 5 | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | (14) | (15) | (94) | (7) | (8) | (9) | (12.8%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (0.02) | 1.24 | (33.35) | (229.14) | (683.91) | (492.20) | (683.9) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | (30.39) | 110.75 | 18.70 | 165.04 | 123.10 | +165.0 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 17 | 18 | 18 | — | +2.9% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Tevogen Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| EXOZ eXoZymes Inc. | $38.1M | — (loss-making) | — | — | n/m | −3.25% (below 0%: shrinking) | — | 0.00% | Compare |
| IBO Impact Biomedical Inc. | $38.0M | — (loss-making) | — | −57.14% (below 0%: shrinking) | n/m | +167.72% (above 0%: growing) | 66.67% | (23,400.00%) | Compare |
| ELTX Elicio Therapeutics, Inc. | $37.9M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRCE Grace Therapeutics, Inc. | $37.5M | — (loss-making) | — (loss-making) | +5,127.27% (above 0%: growing) | n/m | −78.85% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALDX Aldeyra Therapeutics, Inc. | $37.2M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TVGN Tevogen Inc. | $36.2M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | |
| PTHS Pelthos Therapeutics Inc. | $35.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| VERU Veru Inc. | $35.1M | — (loss-making) | — (loss-making) | +99.23% (above 0%: growing) | n/m | +0.27% (above 0%: growing) | 67.84% | 0.00% | Compare |
| LIANY LianBio Sponsored ADR | $34.2M | 0.0× | — | — | n/m | +1,107.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $37.3M | — | — | +21.98% | — | +4.52% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 3 August 2026
Ownership
Directors and executive officers, together
65.60%
Ryan Saadi
57.80%
Manmohan Patel, MD
9.99%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement